araag2/HINT huggingface dataset:
Clinical trial NCT00255164 (phase 3, status: completed)
Conditions: esophagitis, reflux, esophagitis, peptic
ICD codes: K21.9, K21.00, K21.01, B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: dexlansoprazole mr, dexlansoprazole mr, placebo
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have successfully completed the Phase 3 Study T-EE04-084 (NCT00251693)
             or TEE04-085 (NCT00251719); and have healed esophageal erosions proven by endoscopy.
             Complete healing was assessed for change in LA Esophagitis Classification grades A, B,
             C, or D to healed (defined as anything less than the criterion for Grade A). The
             subject was counted as healed if endoscopy findings did not meet the Grade A
             criterion.

        Exclusion Criteria:

          -  Use of prescription or nonprescription proton pump inhibitors (PPIs), histamine (H2)
             receptor antagonists, sucralfate, misoprostol, or prokinetics throughout the study

          -  Use of antacids (except for study supplied) throughout the study.

          -  Subjects using drugs with significant anticholinergic effects such as tricyclics who
             cannot stay on a stable dose throughout the study.

          -  Need for continuous anticoagulant therapy.
Clinical trial NCT01664247 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, placebo, liraglutide
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Insulin naïve

          -  Ongoing treatment with metformin or metformin in combination with either sulphonylurea
             (SU), glinides, dipeptidyl peptidase-IV (DPP-IV) inhibitors or exenatide (only twice
             daily (BID))

          -  Glycosylated haemoglobin (HbA1c) (by central laboratory analysis): a. 7.5-10.0 % (both
             inclusive) for subjects on metformin monotherapy, b. 7.0-9.0 % (both inclusive) for
             subjects on metformin in combination with either SU, glinides, DPP-IV inhibitors or
             exenatide (only BID)

        Exclusion Criteria:

          -  Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria
             within 12 weeks

          -  Calcitonin equal to or above 50 pg/mL

          -  Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial
             infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty; all within 24 weeks

          -  Current or past (within the last 5 years) malignant neoplasms (except basal cell and
             squamous cell carcinoma)
Clinical trial NCT00396227 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, thiazolidinedione (tzd)
SMILES: CN(C)C(=N)NC(N)=N, O=C1CSC(=O)N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have received a stable dose of metformin consisting of at least 1,000
             mg/day for four weeks prior to Visit 1 (week-2)

          -  Agreement to maintain the same dose of metformin from screening to the end of the
             study

          -  Age in the range of 18-80 years

          -  Body mass index (BMI) in the range of 22-40 kg/m2

          -  HbA1c in the range of 7.0 to 10%

          -  FPG <270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  A history of type 1 diabetes

          -  Liver disease

          -  Treatment with insulin or any oral anti-diabetic other than metformin, within 8 weeks
             prior to Visit 1

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00159796 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: asenapine, olanzapine, placebo
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
             diagnosis of bipolar I disorder, current episode manic or mixed.

        Exclusion Criteria:

          -  Participants with unstable medical conditions or clinically significant laboratory
             abnormalities or participants who are rapid cyclers (i.e., have had 4 or more
             (including current) mood episodes in the past 12 months); have any other psychiatric
             disorder other than bipolar I disorder as a primary diagnosis.
Clinical trial NCT00680017 (phase 3, status: completed)
Conditions: dyslipidemia, kidney disease
ICD codes: I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: abt-335 plus rosuvastatin, rosuvastatin
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria

          -  Dyslipidemic participants with Chronic Kidney Disease Stage 3

          -  For entry into the Treatment Phase (Visit 3), the participant satisfied the following
             laboratory criteria (measured at the Screening Visit[s]):

               -  Estimated glomerular filtration rate between 30 and 59 mL/min/1.73 m2 (Chronic
                  Kidney Disease Stage 3) by simplified 4 variable Modification of Diet in Renal
                  Disease formula (this includes a 10 percent variation in the upper limit of
                  estimated glomerular filtration rate that was allowed for the enrollment of
                  participants to account for variability in the creatinine assay).

               -  Fasting lipid results following greater than or equal to 12-hour fasting period:

          -  Triglycerides level greater than or equal to 150 mg/dL,

          -  High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50
             mg/dL for females, and

          -  Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL Exclusion
             Criteria

          -  Participants with certain chronic or unstable medical conditions.

          -  Participants with unstable dose of medications or receiving coumarin anticoagulants,
             systemic cyclosporine, or certain other medications.

          -  Pregnant or lactating women, or women intending to become pregnant.

          -  Participants with diabetes mellitus that is poorly controlled.

          -  Participants of Asian ancestry (having Filipino, Chinese, Japanese, Korean,
             Vietnamese, or Asian-Indian origin).
Clinical trial NCT00730171 (phase 3, status: completed)
Conditions: irritable bowel syndrome with constipation, chronic constipation
ICD codes: K58.1, K59.04
Drugs: linaclotide
SMILES: [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have

               -  entered study MCP-103-303 or MCP-103-302 and at minimum completed the
                  pre-treatment period or

               -  completed one of the following studies: MCP-103-004, MCP-103-005, MCP-103-201,
                  MCP-103-202

          -  Sexually active patients of childbearing potential agree to use birth control

          -  Females of childbearing potential must have a negative urine pregnancy test prior to
             dosing

          -  Lactating females must agree not to breastfeed

          -  Patient must meet protocol criteria for CC or IBS-C

        Exclusion Criteria:

          -  Patient must not use protocol-defined prohibited medicine

          -  Patient is planning to receive an investigational drug at any time during the study

          -  Patient has an unresolved adverse events or a clinically significant finding on a
             physical examination, 12-lead electrocardiogram, or clinical laboratory test
Clinical trial NCT00227747 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the rectum

               -  T3-4, N0-2, M0 disease by endorectal ultrasound

                    -  T2 disease located in the low rectum allowed provided lower pole is ≤ 6 cm
                       from the anal verge

          -  Tumor must be accessible to digital rectal examination (i.e., tumor located at low- or
             mid-rectum)

          -  Resectable disease treatable with chemoradiotherapy

               -  No unresectable disease (i.e., T4 disease with high risk for incomplete gross
                  resection [i.e., R2])

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 80

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin > 10 g/dL

        Hepatic

          -  Alkaline phosphatase normal

          -  Bilirubin normal

        Renal

          -  Creatinine ≤ 130 μmol/L

          -  No severe renal insufficiency

        Cardiovascular

          -  No cardiac insufficiency

          -  No symptomatic coronary artery disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No contraindication to study treatment

          -  Prior acute intestinal obstruction allowed provided patient underwent surgical
             diversion with stoma

          -  No history of other cancer except basal cell skin cancer or carcinoma in situ of the
             cervix

          -  No peripheral neuropathy

          -  No uncontrolled diabetes

          -  No other uncontrolled severe disease

          -  No geographical, social, or psychological condition that would preclude study
             follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for cancer

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy for cancer

        Surgery

          -  Not specified

        Other

          -  No concurrent phenytoin

          -  No concurrent participation in another clinical trial of an experimental medical
             treatment
Clinical trial NCT00132899 (phase 3, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: methotrexate, placebo
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male, or non-pregnant/non-lactating females, 18 or older

          -  Established Crohn's disease with active symptoms requiring prednisone therapy.

          -  Females of child-bearing potential must have a negative pregnancy test and must agree
             to use adequate contraception

        Exclusion Criteria:

          -  Intolerance or hypersensitivity to infliximab, methotrexate, prednisone and or known
             allergy to murine proteins or other chimeric proteins

          -  Are pregnant, nursing, or planning pregnancy (both men and women) during or in the 6
             months after the study

          -  In the 2 months prior to screening, have had a serious infection, or have been
             hospitalized for and/or treated with intravenous (IV) antibiotics for infection. In
             the 6 months prior to screening, have had an opportunistic infection.

          -  After screening, need to continue non-study medical therapy for CD

          -  In the 8 weeks prior to screening, have received any of the following: systemic
             steroid therapy, azathioprine, 6-mercaptopurine, cyclosporine, probiotic products, or
             omega-3 fatty acids

          -  Have received any of the following: biologics in the last 6 months; methotrexate in
             the last year; and/or ever received infliximab.

          -  Have any of the following: biopsy-proven cirrhosis, clinically important lung disease,
             pre-existing demyelinating disorder, systemic lupus erythematosus, congestive heart
             failure, diabetes mellitus (insulin dependent), increased risk for steroid-related
             side effects, body weight 40% higher than standard, human immunodeficiency virus
             and/or hepatitis B or hepatitis C

          -  Have any of the following: an active draining fistula as the primary manifestation of
             CD; documented short bowel syndrome; a stoma; or severe, and/or fixed symptomatic
             stenosis of the intestine.

          -  Have had any of the following: clinically important bowel obstruction in the last 3
             months; a bowel resection in the last 3 months; and/or other intra-abdominal surgery
             within 6 months.

          -  Clinically significant impairment in cardiac, liver or renal function; central nervous
             system (CNS), pulmonary, hematological, immunological, vascular and gastrointestinal
             disease in addition to CD; current malignancy or malignancy within 5 years prior to
             screening.
Clinical trial NCT00626548 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: zd4054, palcebo
SMILES: COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=C1)C1=NN=CO1
Reason stopped: 
    early efficacy review by the independent data monitoring committee indicated it was unlikely to
    meet its primary efficacy endpoints
  
Eligibility criteria:

        Inclusion Criteria:

        Patients who answer TRUE to the following criteria may be eligible to participate in this
        study.

          -  Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT
             spread to the other parts of the body (metastases). Patients with lymph node
             involvement may be eligible if specified criteria is met.

          -  Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment

          -  Currently receiving treatment with surgical or medical castration

        Exclusion Criteria:

        Patients who answer TRUE to the following may NOT be eligible to participate in this study.

          -  Currently using opiate based pain killers for cancer related pain

          -  Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior
             targeted cancer therapies are permitted if received during a previous clinical trial

          -  Suffering from heart failure or had a myocardial infarction within last 6 months

          -  A history of epilepsy or seizures
Clinical trial NCT00568737 (phase 3, status: completed)
Conditions: sepsis
ICD codes: A02.1, A22.7, A26.7, A32.7, A42.7, A54.86, B37.7
Drugs: drotrecogin alfa (activated), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients with recent onset of severe sepsis or presence of a suspected or proven
             infection, and at least one induced organ dysfunction.

        Exclusion Criteria:

          -  Are indicated for the treatment with drotrecogin alfa (activated) under the applicable
             label in the investigative site country.

          -  Are contraindicated for treatment with drotrecogin alfa (activated) under the
             applicable label in the investigative site country.

          -  Platelet count less than 30,000/mm3.
Clinical trial NCT01021332 (phase 3, status: completed)
Conditions: lower urinary tract symptoms, benign prostatic hyperplasia
ICD codes: N40.2, N40.3, N40.0, N40.1, N40.0, N40.1
Drugs: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
SMILES: CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O, CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Completion of 12 weeks double-blind treatment in Study 905-CL-055

        Exclusion Criteria:

          -  Any significant PVR volume (>150 mL)
Clinical trial NCT01202773 (phase 3, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: ly2127399, placebo q4w, placebo q2w
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    terminated not based on safety concerns, but due to insufficient efficacy.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of RA of more than 6 months and less than 15 years

          -  At least 8 tender and swollen joints

          -  An abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate
             (ESR)

          -  Positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP)
             antibody

          -  Previously treated with biologic TNF-α inhibitor therapy (infliximab, certolizumab,
             golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacy
             or intolerance

          -  Regular use of at least 1 conventional disease-modifying anti-rheumatic drug (DMARD),
             with a stable dose for at least 8 weeks prior to study start

          -  Woman must not be pregnant, breastfeeding, or become pregnant during the study

        Exclusion Criteria:

          -  Use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6
             weeks

          -  Steroid injection or intravenous (IV) infusion in the last 6 weeks

          -  Use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks

          -  History of a serious reaction to other biological DMARDs

          -  Use of an oral calcineurin inhibitor (for example, cyclosporin or tacrolimus) in the
             last 8 weeks

          -  Surgery on a joint or other major surgery less than 2 months ago, or plans to have
             joint surgery or major surgery during the study

          -  Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease,
             ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition
             except RA

          -  Cervical cancer or squamous skin cancer within the past 3 years, or other cancer
             within the past 5 years

          -  Received a live vaccine received within the past 12 weeks (for example, vaccines for
             measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)

          -  Hepatitis or human immunodeficiency virus (HIV)

          -  A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months
             or a serious bone or joint infection within 6 months

          -  Symptoms of herpes zoster or herpes simplex within the last month

          -  Active or latent tuberculosis (TB)

          -  Current symptoms of a serious disorder or illness

          -  Use of an investigational drug within the last month
Clinical trial NCT00539942 (phase 3, status: terminated)
Conditions: venous thrombosis
ICD codes: K64.5, I67.6, O87.3, O22.50, O22.51, O22.52, O22.53
Drugs: arixtra (fondaparinux sodium)
SMILES: CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
Reason stopped: 
    problems with accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  All patients undergoing open laparotomy (non-laparoscopic) gynecologic surgery.

          -  Patients must be competent to self-administer injections, or must have caregivers or
             nurses who can perform injections

          -  Patients must have signed an approved informed consent

        Exclusion Criteria:

          -  Patients with medical history which requires chronic anticoagulation (i.e. previous
             DVT, pulmonary embolism, atrial fibrillation, heart valve replacement)

          -  Patients with contraindications to anticoagulation (generalized bleeding disorders,
             peptic ulcer disease, hemorrhagic stroke, etc)

          -  Contraindications to placement of ICDs (history of lower extremity venous stasis
             ulcers)

          -  Patients receiving low molecular weight heparin or unfractionated heparin for
             prophylaxis post-operatively

          -  Patients who are unable to receive injections as an outpatient and/or unable to
             undergo a doppler ultrasound of the lower extremities

          -  Renal insufficiency (creatinine clearance < 30 mL/min)

          -  Patients who have a body weight < 50 kg

          -  Hypersensitivity to low molecular weight heparin

          -  Patients who are pregnant or have a positive pregnancy test.

          -  Patients receiving continuous (indwelling) epidural.
Clinical trial NCT00643045 (phase 3, status: completed)
Conditions: idiopathic parkinson's disease
ICD codes: G20
Drugs: safinamide, safinamide, placebo
SMILES: C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O, C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of idiopathic Parkinson's disease of less than 5 years
             duration, and a Hoehn and Yahr Stage of I to III,

          -  who were receiving treatment with a single dopamine agonist at a stable dose for at
             least 4 weeks prior to Visit 1 (Screening).

        Exclusion Criteria:

          -  Patients with medical conditions and/or taking concomitant medications that would have
             put them at risk, interfered with the study evaluations, or made them unable to
             complete the requirements of the study;

          -  patients with a diagnosis or recent history of substance abuse,

          -  a history of psychosis,

          -  who were depressed,

          -  had evidence of dementia or cognitive dysfunction,

          -  or who were experiencing end of dose wearing-off;

          -  female patients of childbearing potential;

          -  patients who have previously received safinamide.